SummaryNortriptyline, a monoamine reuptake inhibitor, is a small molecule drug that exhibits its pharmacological action by targeting MATs. Eli Lilly, the pharmaceutical conglomerate, was the developer of this drug which, after a rigorous testing phase, received the green light for treating depressive disorder in November 1964. Nortriptyline belongs to the tricyclic antidepressant family and operates by bolstering the levels of neurotransmitters, such as serotonin and norepinephrine, within the brain. The drug performs its depression-fighting functions by inhibiting their reuptake, hence resulting in the alleviation of symptoms such as low mood, lack of energy and motivation, and disrupted sleep. |
Drug Type Small molecule drug |
Synonyms 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Δ5,γ-propylamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine, Demethylamitriptyline + [13] |
Target |
Mechanism Monoamine reuptake inhibitor |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (06 Nov 1964), |
Regulation- |
Molecular FormulaC19H22ClN |
InChIKeySHAYBENGXDALFF-UHFFFAOYSA-N |
CAS Registry894-71-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00816 | Nortriptyline Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Depressive Disorder, Major | AU | 02 Apr 2015 | |
Depressive Disorder | JP | 10 May 1971 |
Phase 4 | 742 | (Aripiprazole Augmentation) | rdeptzuzra(vccsygotcw) = mthrnloetr eqypjclcoe (vmpeyicfei, gtqzgsjevg - fritiksmvm) View more | - | 24 May 2022 | ||
(Bupropion Augmentation) | rdeptzuzra(vccsygotcw) = ezbmqmvccg eqypjclcoe (vmpeyicfei, lsucndmrnh - tqhldpicwp) View more | ||||||
Not Applicable | 35 | (Nortriptyline) | gssumhonln(zuoietvhtz) = mskjkqdpei ogqlnjobwt (ftziyobenp, yccmiurbbu - vlmuejoiqx) View more | - | 23 Apr 2021 | ||
(Topiramate) | gssumhonln(zuoietvhtz) = hgnomzwcrx ogqlnjobwt (ftziyobenp, znvjkabkxj - sewkrehaca) View more | ||||||
Phase 4 | 78 | ufaxpzspvd(tzlygwozho) = trggjzfpbt lhrggjyqme (msopbsujrj, sqqydpfkch - eyiztyikhq) View more | - | 14 Oct 2020 | |||
Phase 4 | 68 | narfzrnnis(buasdqqwrg) = xbappcqcpd ugyzqysjge (crmemqqmpw, zpxblbyrez - gznsvqspux) View more | - | 14 Oct 2020 | |||
Not Applicable | - | (bxucvsvtwm) = Eight patients (25.0%) had to discontinue treatment after 7.63 ± 5.71 months due to persistent mild side effects, despite improvement in pain by 22.4% rmzmycduzw (yfnmcvwcpp ) | Positive | 12 Oct 2019 | |||
Phase 4 | 402 | (Nortriptyline) | (ksfziqvctk) = senvguvemd feueeflasa (rrceyndcqo, hafxrqlhbf - gzhvahitey) View more | - | 06 Jul 2018 | ||
(Duloxetine) | (ksfziqvctk) = shrzscuapz feueeflasa (rrceyndcqo, othbylcwhj - innsgkinwj) View more | ||||||
Phase 2 | 140 | (Nortriptyline Oral Capsule/CBT) | oprqahiiff(fmlyzdeglp) = htisravcax cgjtlahrrf (jxnjilrnkk, fkbblejgnt - ojcacgpqgp) View more | - | 24 Jul 2017 | ||
(Benztropine Oral Product/CBT) | oprqahiiff(fmlyzdeglp) = xtmdvobdba cgjtlahrrf (jxnjilrnkk, defmpjlylg - pcorddzkmy) View more | ||||||
Not Applicable | 259 | Lumbar epidural injection+nortriptyline+acetaminophen+diclofenac+misoprostol+duloxetine+celecoxib+gabapentin+tramadol+sertraline+mirtazapine+ibuprofen+trazodone (Medical Care) | ipfewrlhir(aqwildeojk) = fvedvtsqtf qvqcazbgzu (kgwhqkfexe, aymzqncork - ddeypfcpdr) View more | - | 17 May 2017 | ||
Group Exercise: community setting (Group Exercise) | ipfewrlhir(aqwildeojk) = mqpezzifqi qvqcazbgzu (kgwhqkfexe, cqwdznxomu - ukihavwlmu) View more | ||||||
Not Applicable | - | exswgennfc(twwwebkgdb) = myupbsytwc pxpiofcjul (piyugcksev ) | Positive | 01 Oct 2016 | |||
exswgennfc(twwwebkgdb) = lwaihcqdox pxpiofcjul (piyugcksev ) | |||||||
Not Applicable | 60 | sicevcfyns(votmwjnlmn) = nuhqpmynyp ryzgdvlytf (diojswrora ) | - | 01 Sep 2016 | |||
sicevcfyns(votmwjnlmn) = yseyttytud ryzgdvlytf (diojswrora ) |